In a recent analysis, BTIG reaffirmed its confidence in Humacyte (HUMA) by upholding a 'Buy' rating, even as it revised the price target downward from $6 to $3. This decision came after Humacyte's release of its fourth-quarter and full-year 2025 earnings report. The company disclosed fourth-quarter revenue of $0.5 million and full-year revenue of $2.0 million, figures that fell short of BTIG's projection of $1.3 million for the quarter. Additionally, Humacyte reported a loss per share of $0.13, slightly wider than the consensus estimate of a $0.12 loss.

BTIG acknowledged the uneven progression of Symvess in the trauma sector, noting a decrease in units sold to approximately 25 in the fourth quarter from 29 in the preceding quarter of 2025, alongside a reduction in the average price per unit from $24,500 to roughly $17,000. Concerns were also raised regarding elevated operational costs, emphasizing the critical importance of cash management for the company. Despite these setbacks, BTIG highlighted positive commercial traction, evidenced by an increase in hospitals adopting Symvess for trauma care, growing from 16 to 27 facilities. Humacyte further secured a minimum purchase commitment of $1.475 million for a clinical evaluation and outreach initiative in Saudi Arabia, and both the company and BTIG eagerly anticipate the interim top-line results from the Phase 3 V012 study for dialysis access, expected in the second quarter of 2026, pointing to a significantly larger market opportunity than trauma.

Humacyte Inc. is at the forefront as a commercial-stage biotechnology firm, dedicated to advancing universally implantable, bioengineered human tissues. This commitment positions the company to potentially revolutionize treatment options, offering innovative solutions for patients globally. Through continued research and strategic market development, Humacyte aims to overcome current challenges and realize its vision of impactful medical advancements, paving the way for a healthier future.